Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE PHASE 1B PROGRAM IS DESIGNED TO EVALUATE THE CLINICAL ACTIVITY OF NXP900 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS WHOSE CANCERS HARBOR SPECIFIC GENETIC ALTERATIONS, AND IN COMBINATION WITH EGFR AND ALK INHIBITORS IN PATIENTS WITH NSCLC WHOSE CANCERS DEVELOPED RESISTANCE TO THESE TREATMENTS NUVECTIS WILL HOLD A CONFERENCE CALL TOMORROW, TUESDAY, AUGUST 12 AT 8:30 AM ET TO DISCUSS THE ELEMENTS OF THE PHASE 1B PROGRAM AND THE OVERALL MARKET OPPORTUNITY FOR NXP900 FORT LEE, NJ, AUG. 11, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THE INITIATION OF THE PHASE 1B PROGRAM FOR NXP900. NXP900 PHASE 1B CLINICAL PROGRAM THE PHASE 1B PROGRAM WAS INITIATED FOLLOWING THE SUCCESSFUL COMPLETION OF A DOSE ESCALATION STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS AND A CLINICAL DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEER, AND IS INTENDED TO INCLUDE A SINGLE AGENT COMPONENT, WHICH IS NOW UNDERWAY, AND A COMBINATION COMPONENT THAT IS EXPECTED TO COMMENCE LATER THIS YEAR.

NUVECTIS PHARMA ANNOUNCES THE INITIATION OF THE PHASE 1B PROGRAM FOR NXP900

FORT LEE, N.J., AUG. 05, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND PROVIDED AN UPDATE ON RECENT BUSINESS PROGRESS.

NUVECTIS PHARMA, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

AVAILABLE DATA FROM 13 PATIENTS WITH RECURRENT, PLATINUM RESISTANT, ARID1A-MUTATED OVARIAN CANCER TREATED WITH 75 MG/DAY IN THE NXP800 PHASE 1B STUDY INCLUDES 2 PARTIAL RESPONSES AND 3 STABLE DISEASES; THROMBOCYTOPENIA SUCCESSFULLY MANAGED WITH INTERMITTENT DOSING SCHEDULE; OBSERVED CLINICAL ACTIVITY WARRANTS EXPLORATION OF POTENTIAL DEVELOPMENT OPPORTUNITIES IN OTHER CANCER TYPES NXP900 SUCCESSFULLY COMPLETED A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY IN HEALTHY VOLUNTEERS AND THE PHASE 1A DOSE ESCALATION STUDY; INITIATION OF THE NXP900 PHASE 1B PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF NXP900 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS EXPECTED IN THE COMING WEEKS FORT LEE, NJ, JULY 31, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY PROVIDED THE FINAL CLINICAL DATA UPDATE FROM THE PHASE 1B STUDY OF NXP800 IN RECURRENT, PLATINUM RESISTANT, ARID1A-MUTATED OVARIAN CANCER AND REPORTED ON THE PROGRESS TOWARDS THE INITIATION OF THE PHASE 1B PROGRAM FOR NXP900. AS PART OF THE NXP800 PHASE 1B STUDY, 17 PATIENTS WITH RECURRENT, PLATINUM RESISTANT, ARID1A-MUTATED OVARIAN CANCER WERE TREATED WITH NXP800 AT THE TARGET DOSE OF 75 MG/DAY, ADMINISTERED INTERMITTENTLY OR DAILY, WITH DATA AVAILABLE FOR 13 PATIENTS.

NUVECTIS PHARMA PROVIDES FINAL CLINICAL DATA UPDATE FROM THE NXP800 PHASE 1B STUDY IN OVARIAN CANCER AND REPORTS COMPLETION OF THE NXP900 PHASE 1A DOSE ESCALATION STUDY

FORT LEE, NJ, MAY 16, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THAT RON BENTSUR, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE 3RD ANNUAL H.C. WAINWRIGHT GLOBAL BIOCONNECT INVESTOR CONFERENCE.

NUVECTIS PHARMA TO PRESENT AT THE H.C. WAINWRIGHT BIOCONNECT INVESTOR CONFERENCE

FORT LEE, N.J., MAY 06, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER 2025 AND PROVIDED AN UPDATE ON RECENT BUSINESS PROGRESS.

NUVECTIS PHARMA, INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

PHASE 1A DOSE-ESCALATION STUDY DATA UPDATE: TREATMENT WITH NXP900 RESULTED IN EXPOSURE LEVELS LEADING TO ROBUST PHARMACODYNAMIC RESPONSES ACROSS A RANGE OF TOLERATED DOSES; NXP900 HAS AN ACCEPTABLE SAFETY PROFILE, DOSE LIMITING TOXICITY DOSE LEVEL HAS NOT BEEN IDENTIFIED IN DOSES UP TO 250 MG/DAY PRECLINICAL POSTERS STRENGTHEN THE NXP900 CLINICAL DEVELOPMENT STRATEGY AS SINGLE AGENT IN BIOMARKER-TARGETED CANCERS AND IN COMBINATION WITH MARKET LEADING THERAPIES TO OVERCOME RESISTANCE IN NSCLC FORT LEE, NJ, APRIL 29, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY TODAY PROVIDED POSTER PRESENTATION HIGHLIGHTS FOR NXP900 FROM THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH MEETING (2025 AACR). THESE POSTERS HIGHLIGHT KEY DATA SUPPORTING THE RATIONALE FOR THE PHASE 1B PROGRAM IN BIOMARKER-SELECTED CANCERS AS A SINGLE AGENT, AND IN COMBINATION WITH MARKET LEADING THERAPIES TO OVERCOME TREATMENT RESISTANCE IN NON-SMALL CELL LUNG CANCER (NSCLC).

NUVECTIS PHARMA PROVIDES POSTER PRESENTATION HIGHLIGHTS FOR NXP900 FROM THE 2025 AACR MEETING

FORT LEE, NJ, MARCH 14, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NUVECTIS, COMPANY), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THAT RON BENTSUR, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 37TH ANNUAL ROTH CONFERENCE TAKING PLACE MARCH 17TH-19TH IN DANA POINT, CALIFORNIA.

NUVECTIS PHARMA TO PARTICIPATE IN THE 37TH ANNUAL ROTH CONFERENCE

NEW YORK--(BUSINESS WIRE)---- $NVCT #CANCERSTOCKS--MARKET NEWS ALERTS REPORTS: NUVECTIS PHARMA (NASDAQ: NVCT)* ANNOUNCED TODAY THAT NEW INDEPENDENT RESEARCH CONDUCTED AT THE LERNER RESEARCH INSTITUTE, CLEVELAND CLINIC (AT CASE WESTERN RESERVE UNIVERSITY) HAS DEMONSTRATED THE SUPERIOR EFFICACY OF NXP900 WHEN COMBINED WITH OSIMERTINIB (TAGRISSO) IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) MODELS. THE PEER-REVIEWED STUDY, PUBLISHED IN MOLECULAR CANCER RESEARCH, DEMONSTRATED THAT THE COMBINATION THERAPY LED TO DEC.

MARKET NEWS ALERT: NUVECTIS PHARMA'S NXP900 DEMONSTRATES SUPERIOR EFFICACY IN NSCLC WHEN COMBINED WITH TAGRISSO IN CLEVELAND CLINIC STUDY, FOLLOWING NEW BUY RECOMMENDATION

NEW YORK--(BUSINESS WIRE)---- $NVCT #PHARMA--MARKET NEWS ALERTS REPORTS: LUCID CAPITAL MARKETS HAS INITIATED COVERAGE ON NUVECTIS PHARMA (NASDAQ: NVCT) WITH A BUY RATING AND A PRICE TARGET OF $18. THE FIRM'S REPORT HIGHLIGHTS NUVECTIS' PROMISING ONCOLOGY PIPELINE, PARTICULARLY ITS LEAD ASSET, NXP900, A SRC/YES1 INHIBITOR TARGETING SQUAMOUS CELL CARCINOMAS WITH HIGH UNMET NEED. LUCID'S REPORT EMPHASIZES THE STRONG POTENTIAL OF NXP900, WHICH IS CURRENTLY IN PHASE 1 CLINICAL TRIALS AND HAS SHOWN AN ENCOURAGING SAFE.

MARKET NEWS ALERT: NUVECTIS PHARMA RECEIVES $18 PRICE TARGET AND BUY RATING FROM LUCID CAPITAL MARKETS

FORT LEE, NJ, FEB. 07, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 2,700,000 SHARES OF ITS COMMON STOCK, AND THE EXERCISE IN FULL OF THE UNDERWRITER'S OPTION TO PURCHASE 405,000 ADDITIONAL SHARES. THE COMMON STOCK SHARES WERE OFFERED AT A PRICE OF $5.00 PER SHARE, RESULTING IN GROSS PROCEEDS TO NUVECTIS OF APPROXIMATELY $15.5 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS.

NUVECTIS PHARMA ANNOUNCES CLOSING OF $15.5 MILLION PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE OF UNDERWRITER'S OVER-ALLOTMENT OPTION

FORT LEE, N.J., FEB. 05, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 2,700,000 SHARES OF ITS COMMON STOCK AT A PRICE OF $5.00 PER SHARE, WITH EXPECTED GROSS PROCEEDS TO NUVECTIS OF $13.5 MILLION. NUVECTIS HAS ALSO GRANTED THE UNDERWRITER A 30-DAY OPTION TO PURCHASE UP TO 405,000 ADDITIONAL SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON FEBRUARY 6, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

Nuvectis Pharma, Inc.

NVCT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nuvectis Pharma, Inc.

NVCT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NVCT